In general, use of a vascular closure device after transfemoral percutaneous coronary intervention (PCI) decreases the risk of vascular complications, according to a large registry study of real-world ...

Innovative Patient-Friendly Device Combines Safety of Extravascular Sealant and Security of Mechanical Closure to Provide Consistent Results “We are proud of the advantages Mynx Ace offers to femoral ...

Please provide your email address to receive an email when new articles are posted on . HOLLYWOOD, Fla. — While there is not yet definitive evidence that vascular closure devices produce better ...

BURLINGTON, MA — An active surveillance system now available as an open-source tool found that the relative risk of vascular complications was increased 60% for patients receiving Mynx (Cardinal ...

Please provide your email address to receive an email when new articles are posted on . In an analysis of the ISAR-CLOSURE trial, use of vascular closure devices was as safe and effective as manual ...

Patients who underwent surgery to repair punctured arteries had a significantly higher risk of complications when surgeons used a vascular-closure device manufactured by Cardinal Health, compared to ...

A head-to-head comparison of vascular closure devices defied expectations in the CHOICE-CLOSURE trial. For large-bore arterial access site closure after transfemoral transcatheter aortic valve ...

NEW YORK, Oct. 29, 2019 /PRNewswire/ -- Vascular Closure Device market worldwide is projected to grow by US$413.8 Million, driven by a compounded growth of 6.6%. Passive Approximators, one of the ...

BOSTON, June 18, 2024 /PRNewswire/ -- Haemonetics Corporation (HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has launched a ...

Chicago, IL - A new vascular closure device with a bioabsorbable plug has shown impressive results in a pivotal multicenter trial, ECLIPSE. The device, named ExoSeal (Cordis), also has a unique ...

Cardiva Medical raised $30 million in equity, which will bankroll the commercial expansion of its bioabsorbable vascular closure system and advance technologies in its pipeline. The company’s Vascade ...

Earlier this week, Needham downgraded Haemonetics from “Buy” to “Hold,” pointing to intensifying competition in vascular closure devices from Abbott and Cordis and warning that this could weigh on the ...